



Quest Diagnostics Appoints Kenneth Finnegan to Lead Business Development Efforts

May 18, 2000

TETERBORO, N.J., May 18, 2000 —

Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic laboratory testing, information and services, announced it has appointed Kenneth R. Finnegan to lead its business development efforts.

In the newly created position of Corporate Vice President, Business Development, Mr. Finnegan will be responsible for building upon Quest Diagnostics' market leadership position and accelerating profitable growth. He will focus on identifying, assessing and executing strategic transactions with a particular emphasis on targeted growth areas including esoteric and genetic testing, medical information and direct-to-consumer services. He will report directly to Kenneth W. Freeman, Chairman and Chief Executive Officer.

Mr. Finnegan joined Quest Diagnostics as Vice President, Treasurer, in July 1997. He will retain responsibility for investor relations until a successor is named.

Before joining Quest Diagnostics, Mr. Finnegan had been Assistant Treasurer at General Signal Corporation in Stamford, Conn. He also worked on the corporate staffs of International Paper Company and Texaco, Inc.

Quest Diagnostics is the nation's leading provider of diagnostic testing, information and services with annualized revenues of more than \$3 billion. The testing performed on human specimens helps doctors diagnose, treat and monitor disease; enables employers to detect workplace drug abuse; and supports pharmaceutical and biotechnology companies in clinical trials of new therapeutics worldwide. Quest Informatics analyzes laboratory and other medical data to help health care providers improve the care of patients. Additional company information can be found on the Internet at: www.questdiagnostics.com.

The statements in this press release which are not historical facts or information may be forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the outcome to be materially different. Certain of these risks and uncertainties are listed in the Quest Diagnostics Incorporated 1999 Form 10-K and subsequent filings.